Biomarkers
Biomarkers are the core of today's drug development, especially in the field of tumor. Clinical studies using biomarkers have a higher success rate of drug development than those without biomarkers.
Biomarkers are important tools to improve the efficiency of drug development. The exploration of biomarkers with different functions should run through the early development, preclinical research and the whole clinical development stage. The functions of biomarkers are different. Biomarkers should be reasonably selected and used according to the application purposes of different drug development stages. Our scientific team will match your research with biomarker solutions based on the disease characteristics of the patient population, the mechanism of action of the drug, the safety characteristics, the intended use of the biomarker, and many other factors.
We have one of the most extensive lists of routine and specialized tests in the industry, innovative cutting-edge technology platforms and a scientific team that provides expertise and advice. Customized biomarker solutions for your drug clinical trials, ranging from standard clinical tests to new/exploratory/customized biomarker tests. We have completed the development and validation of more than 4,000 biomarker tests.
For exploratory biomarkers in early clinical trial stage
For new/exploratory/customized biomarkers, our scientific team will propose appropriate technology platforms for research and development verification based on deep expertise (treatment field, research program, drug mechanism, understanding of biomarkers, etc.) and will consider the research and development time and cost.
It is recommended to cooperate with the KingMylab team as soon as possible to explore appropriate biomarkers in the early clinical trial stage. According to the results of the study of biomarkers in early clinical trials, it is clear whether to use a certain biomarker for population enrichment and confirm it in key clinical trials. It is suggested that after the enrichment scheme of the population is clarified, the development of the companion diagnostic device reagent should be planned as soon as possible.
For clinically meaningful biomarkers
Our scientific team will follow clinical guidelines, consensus and other industry experts to provide biomarker solutions.
